Tonix Pharm Hldg Cor (TNXP) 6.73 $TNXP Premarket Gainers

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:54 PM

Tonix Pharm Hldg Cor (TNXP) 6.73 $TNXP

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 21, 8:22AM CDT

HOG: 56.23 (+0.51), TNXP: 6.73 (+0.21), ALNY: 118.00 (-2.70), LRE: 8.43 (+0.08), LRCX: 78.36 (+0.52), MYL: 72.40 (-1.67), NVGN: 7.40 (-0.30), BIOC: 3.15 (+0.02), NBG: 1.19 (+0.12), VLTC: 15.14 (-1.04), FTNT: 38.07 (-0.01), BCLI: 4.29 (-0.09), SANM: 21.09 (+0.40)

Tonix Pharmaceuticals: Four Data-Based Valuations Of A Deeply Underappreciated Pharmaceutical Company
Jeff Eiseman - at Seeking Alpha - Tue Apr 21, 6:15AM CDT

TNXP: 6.73 (+0.21)

Entries For Seeking Alpha's Contrarian Idea Contest
SA Editor Daniel Shvartsman - Seeking Alpha - Mon Apr 20, 6:21AM CDT
Contrarian thinking is a fundamental part of both active investing and Seeking Alpha - one can't beat the market by agreeing with it. Our latest contest pays homage to that idea. We're looking for the best investment ideas that fit into the...
NFLX: 557.68 (-2.76), BXE: 3.13 (unch), ENPH: 13.38 (+0.03), NEON: 4.45 (+0.23), SEAS: 20.91 (+0.05), TNXP: 6.73 (+0.21), GBX: 64.37 (+0.56), RY: 65.41 (+0.06), INVN: 16.13 (+0.42), PPC: 24.36 (+0.16)

SeeThruEquity Issues Company Update on Tonix Pharmaceuticals, Maintaining Price Target of $14.02
ACCESSWIRE - Tue Apr 07, 6:16PM CDT
NEW YORK, NY / ACCESSWIRE / April 7, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company update on Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP).
TNXP: 6.73 (+0.21)

Biotech Weekly: Top Value Biotech Picks Starting Q2 2015
Daniel Ward - at Seeking Alpha - Mon Mar 30, 8:43AM CDT

LOXO: 13.21 (-0.01), TENX: 3.51 (+0.01), QLTI: 3.75 (-0.04), ECYT: 6.37 (unch), TNXP: 6.73 (+0.21), BOTA: 2.34 (-0.02), XBI: 232.63 (-0.32), DARA: 0.75 (+0.02), IBB: 363.84 (-0.66), MEIP: 2.08 (-0.16)

Tonix Pharmaceuticals to Present at the 12th Annual BIO Asia International Conference
GlobeNewswire - Fri Mar 20, 10:30AM CDT
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP), a pharmaceutical company with clinical-stage development programs in fibromyalgia, post-traumatic stress disorder (PTSD), and episodic tension-type headache, will present at the 12 Annual BIO Asia International Conference to be held at the Grand Hyatt in Tokyo, Japan. Seth Lederman, M.D., president and CEO of Tonix, will deliver a corporate overview on Tuesday, March 24, 2015 at 11:45 a.m. Japan Time.
TNXP: 6.73 (+0.21)

Tonix Pharma net loss worsens in Q4 and FY14
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 7:49AM CST

TNXP: 6.73 (+0.21)

Tonix reports 4Q loss
Automated Insights - Tue Mar 03, 7:15AM CST
NEW YORK (AP) _ Tonix Pharmaceuticals Holding Corp. (TNXP) on Tuesday reported a loss of $9 million in its fourth quarter.
TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals misses by $0.02
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 7:12AM CST

TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Tue Mar 03, 7:00AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) announced financial results for the fourth quarter and full year ended December 31, 2014. Tonix filed its Annual Report on Form 10-K for fiscal year 2014 on Friday, February 27, 2015.
TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals to Present at the 8th Annual European Life Sciences CEO Forum
GlobeNewswire - Mon Mar 02, 7:40AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 8 Annual European Life Sciences CEO Forum & Exhibition in Zurich, Switzerland. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on Tuesday, March 3 at 2:30 p.m. local time. Earlier that day, Dr. Lederman will participate as a speaker at a Neuroscience Panel at the conference, to be held at 12:00 p.m. local time.
TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals raises USD28.7m from public offering
M2 - Tue Feb 10, 6:28AM CST
Medicine company Tonix Pharmaceuticals Holding (NasdaqGM:TNXP) disclosed on Monday the completion of its public offering of 4.9m shares of its common stock.
TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals Announces Closing of $28.7 Million Public Offering of Common Stock
GlobeNewswire - Mon Feb 09, 12:45PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the closing of its previously announced underwritten public offering of 4,900,000 shares of its common stock. The shares were sold at the public offering price of $5.85 per share, bringing the aggregate gross proceeds from the offering to approximately $28.7 million, before deducting underwriting discounts and commissions and other offering expenses. Investors in the offering included Broadfin Capital LLC, Deerfield Management Company, L.P., Sabby Management LLC and others.
TNXP: 6.73 (+0.21)

Nasdaq stocks posting largest volume increases
AP - Thu Feb 05, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ADEP: 6.38 (+0.09), TFSC: 9.70 (+0.09), TNXP: 6.73 (+0.21), QKLS: 2.33 (-0.21), EOPN: 8.59 (unch), HPJ: 4.19 (+0.03), PEGI: 29.82 (+0.08), SABR: 25.21 (-0.03), BPFH: 12.50 (+0.13), SBCP: 12.35 (+0.19), ENTR: 3.08 (+0.02), HTWO: 9.70 (-0.11), ACFC: 4.18 (-0.01), OHGI: 1.74 (-0.01)

Tonix Pharmaceuticals to Present at the BIO CEO & Investor Conference
GlobeNewswire - Thu Feb 05, 10:01AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) will present at the 17 Annual BIO CEO and Investor Conference in New York City. Seth Lederman, M.D., Tonix's president and chief executive officer, will deliver a corporate overview on Tuesday, February 10 at 9:30 a.m. ET.
TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals prices public offering of common shares at USD5.85 per share
M2 - Thu Feb 05, 5:48AM CST
Pharmaceutical company Tonix Pharmaceuticals Holding (NasdaqGM:TNXP) said on Wednesday that it has priced a public offering of 4,900,000 shares of its common stock at USD5.85 per share.
TNXP: 6.73 (+0.21)

Tonix Pharma prices equity offering
Seeking Alpha - at Seeking Alpha - Wed Feb 04, 8:05AM CST

TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals Prices Underwritten Public Offering of Common Stock
GlobeNewswire - Wed Feb 04, 7:15AM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced the pricing of an underwritten public offering of 4,900,000 shares of its common stock at a price of $5.85 per share. The company has also granted to the underwriters a 45-day option to acquire an additional 735,000 shares to cover overallotments in connection with the offering. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.7 million, assuming no exercise of the overallotment option. The offering is expected to close on February 9, 2015, subject to customary closing conditions.
TNXP: 6.73 (+0.21)

Tonix Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire - Tue Feb 03, 3:18PM CST
Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) today announced that it intends to offer shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
TNXP: 6.73 (+0.21)

Tonix Shares Looking Attractive As Clinical Programs Advance Forward
Jason Napodano, CFA - at Seeking Alpha - Wed Jan 28, 9:00AM CST

TNXP: 6.73 (+0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

ManuTech Center Set to Revolutionize Manufacturing Hub

Jackson's Next Manufacturing Frontier Well, the folks down in Jackson, Michigan, are prepping to cut the red ribbon on something that's got me leaning forward in my seat. The Advanced Manufacturing Training Center (AMTC) is pulling out all the stops with their new ManuTech Prototyping Center. Yup, this center is about to become the playground for startups, manufacturers,...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

HiTHIUM Joins Cambridge to Boost Global Energy Storage

HiTHIUM and Cambridge's New Energy Venture There's a big splash coming out of Xiamen, folks. HiTHIUM, a heavyweight in the energy storage sector, has decided to team up with the University of Cambridge. They inked a deal aiming to bridge the academic ivory tower with industrial grit, focusing on long-duration energy storage. It was all sealed during the Global Energy...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....